Portfolio Holdings Detail for ISIN IE00B3VWM098

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE

Holdings detail for INVA

Show aggregate INVA holdings

News associated with INVA

Innoviva (NASDAQ:INVA) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded shares of Innoviva (NASDAQ:INVA – Free Report) from a buy rating to a strong-buy rating in a report released on Monday morning. Several other analysts also recently weighed in on INVA. Cantor Fitzgerald began coverage on Innoviva in a research report on Friday, July 11th. They issued an “overweight” rating and […] - 2025-09-02 03:06:54

Comparing Innoviva (NASDAQ:INVA) and Novo Nordisk A/S (NYSE:NVO)

Innoviva (NASDAQ:INVA – Get Free Report) and Novo Nordisk A/S (NYSE:NVO – Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings. Institutional & Insider Ownership 99.1% of Innoviva shares […] - 2025-09-01 03:01:00

Deutsche Bank AG Trims Stock Position in Innoviva, Inc. (NASDAQ:INVA)

Deutsche Bank AG decreased its position in shares of Innoviva, Inc. (NASDAQ:INVA – Free Report) by 4.2% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 827,730 shares of the biotechnology company’s stock after selling 36,549 shares during the quarter. Deutsche Bank AG owned approximately […] - 2025-08-15 05:51:00

Innoviva (NASDAQ:INVA) and AbbVie (NYSE:ABBV) Financial Comparison

Innoviva (NASDAQ:INVA – Get Free Report) and AbbVie (NYSE:ABBV – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership. Profitability This table compares Innoviva and AbbVie’s net margins, return […] - 2025-08-13 04:40:48

Innoviva (NASDAQ:INVA) Stock Price Up 8.2% on Analyst Upgrade

Innoviva, Inc. (NASDAQ:INVA – Get Free Report) shares were up 8.2% on Monday after HC Wainwright raised their price target on the stock from $40.00 to $45.00. HC Wainwright currently has a buy rating on the stock. Innoviva traded as high as $19.66 and last traded at $19.84. Approximately 205,104 shares traded hands during trading, […] - 2025-08-13 02:55:07

Innoviva (NASDAQ:INVA) and AbbVie (NYSE:ABBV) Head-To-Head Review

Innoviva (NASDAQ:INVA – Get Free Report) and AbbVie (NYSE:ABBV – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations. Earnings & Valuation This table compares Innoviva and AbbVie”s gross […] - 2025-08-06 04:40:51

Principal Financial Group Inc. Grows Stock Position in Innoviva, Inc. (NASDAQ:INVA)

Principal Financial Group Inc. boosted its stake in Innoviva, Inc. (NASDAQ:INVA – Free Report) by 2.6% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 305,476 shares of the biotechnology company’s stock after acquiring an additional 7,700 shares during the quarter. […] - 2025-07-17 05:51:13

Innoviva (NASDAQ:INVA) vs. Merck & Co., Inc. (NYSE:MRK) Head to Head Comparison

Innoviva (NASDAQ:INVA – Get Free Report) and Merck & Co., Inc. (NYSE:MRK – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership. Earnings & Valuation This table compares Innoviva […] - 2025-07-17 04:38:50

New York State Teachers Retirement System Has $1.04 Million Holdings in Innoviva, Inc. (NASDAQ:INVA)

New York State Teachers Retirement System lessened its holdings in shares of Innoviva, Inc. (NASDAQ:INVA – Free Report) by 5.7% during the first quarter, Holdings Channel.com reports. The institutional investor owned 57,498 shares of the biotechnology company’s stock after selling 3,448 shares during the quarter. New York State Teachers Retirement System’s holdings in Innoviva were […] - 2025-07-10 04:59:01

Illinois Municipal Retirement Fund Reduces Stock Position in Innoviva, Inc. (NASDAQ:INVA)

Illinois Municipal Retirement Fund lowered its stake in Innoviva, Inc. (NASDAQ:INVA – Free Report) by 4.3% during the 1st quarter, HoldingsChannel reports. The firm owned 27,806 shares of the biotechnology company’s stock after selling 1,260 shares during the period. Illinois Municipal Retirement Fund’s holdings in Innoviva were worth $504,000 as of its most recent filing […] - 2025-07-04 04:46:49

Exchange Traded Concepts LLC Grows Stock Holdings in Innoviva, Inc. (NASDAQ:INVA)

Exchange Traded Concepts LLC grew its holdings in Innoviva, Inc. (NASDAQ:INVA – Free Report) by 8.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 176,025 shares of the biotechnology company’s stock after purchasing an additional 14,020 shares during the quarter. Exchange […] - 2025-06-17 06:15:01

FDA Grants Priority Review For Innoviva's Zoliflodacin For Treatment Of Uncomplicated Gonorrhea

(RTTNews) - Innoviva Specialty Therapeutics, Inc., a unit of Innoviva, Inc. (INVA), in partnership with the Global Antibiotic Research & Development Partnership (GARDP), Thursday said that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Ap - 2025-06-12 08:48:08

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Buys 1,162 Shares of Innoviva, Inc. (NASDAQ:INVA)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Innoviva, Inc. (NASDAQ:INVA – Free Report) by 3.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 31,490 shares of the biotechnology company’s stock after acquiring an additional 1,162 shares […] - 2025-05-29 05:40:50

Two Sigma Investments LP Has $4.56 Million Stock Position in Innoviva, Inc. (NASDAQ:INVA)

Two Sigma Investments LP reduced its position in shares of Innoviva, Inc. (NASDAQ:INVA – Free Report) by 45.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 262,739 shares of the biotechnology company’s stock after selling 221,073 shares […] - 2025-05-28 05:20:52

10,612 Shares in Innoviva, Inc. (NASDAQ:INVA) Purchased by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC purchased a new position in Innoviva, Inc. (NASDAQ:INVA – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 10,612 shares of the biotechnology company’s stock, valued at approximately $184,000. Other hedge funds and other institutional investors also […] - 2025-05-19 04:38:50

Sum Up The Parts: IJR Could Be Worth $128

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-05-15 07:40:06

MetLife Investment Management LLC Acquires 1,731 Shares of Innoviva, Inc. (NASDAQ:INVA)

MetLife Investment Management LLC raised its holdings in shares of Innoviva, Inc. (NASDAQ:INVA – Free Report) by 5.2% in the 4th quarter, Holdings Channel reports. The firm owned 34,961 shares of the biotechnology company’s stock after purchasing an additional 1,731 shares during the quarter. MetLife Investment Management LLC’s holdings in Innoviva were worth $607,000 at […] - 2025-05-05 05:30:51

Innoviva (NASDAQ:INVA) Upgraded by StockNews.com to “Buy” Rating

Innoviva (NASDAQ:INVA – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday. Separately, Scotiabank started coverage on shares of Innoviva in a report on Friday, March 7th. They issued a “sector outperform” rating and a $55.00 […] - 2025-05-02 02:46:47

Dimensional Fund Advisors LP Grows Position in Innoviva, Inc. (NASDAQ:INVA)

Dimensional Fund Advisors LP raised its position in Innoviva, Inc. (NASDAQ:INVA – Free Report) by 4.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,919,518 shares of the biotechnology company’s stock after buying an additional 226,592 shares during the […] - 2025-04-30 06:00:57

Look Under The Hood: IJR Has 39% Upside

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-04-14 09:05:39

Innoviva (NASDAQ:INVA) Downgraded to “Hold” Rating by StockNews.com

Innoviva (NASDAQ:INVA – Get Free Report) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Tuesday. Separately, Scotiabank started coverage on shares of Innoviva in a research report on Friday, March 7th. They set a “sector outperform” rating and a $55.00 target price […] - 2025-04-03 02:27:03

72,400 Shares in Innoviva, Inc. (NASDAQ:INVA) Acquired by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS acquired a new stake in shares of Innoviva, Inc. (NASDAQ:INVA – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 72,400 shares of the biotechnology company’s stock, valued at approximately $1,256,000. KLP Kapitalforvaltning AS owned 0.12% of Innoviva as […] - 2025-03-30 06:16:54

Innoviva (NASDAQ:INVA) Upgraded by StockNews.com to “Buy” Rating

StockNews.com upgraded shares of Innoviva (NASDAQ:INVA – Free Report) from a hold rating to a buy rating in a research note published on Monday morning. Separately, Scotiabank began coverage on Innoviva in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $55.00 target price on the stock. Read Our […] - 2025-03-25 04:09:01

Innoviva (NASDAQ:INVA) Upgraded at StockNews.com

StockNews.com upgraded shares of Innoviva (NASDAQ:INVA – Free Report) from a hold rating to a buy rating in a report released on Friday. Separately, Scotiabank started coverage on Innoviva in a research report on Friday. They set a “sector outperform” rating and a $55.00 price objective on the stock. Check Out Our Latest Analysis on […] - 2025-03-10 04:28:55

Scotiabank Begins Coverage on Innoviva (NASDAQ:INVA)

Scotiabank began coverage on shares of Innoviva (NASDAQ:INVA – Free Report) in a research report released on Friday morning, MarketBeat Ratings reports. The brokerage issued a sector outperform rating and a $55.00 target price on the biotechnology company’s stock. Separately, StockNews.com cut Innoviva from a “buy” rating to a “hold” rating in a research report […] - 2025-03-10 04:28:54

Illinois Municipal Retirement Fund Increases Holdings in Innoviva, Inc. (NASDAQ:INVA)

Illinois Municipal Retirement Fund increased its stake in Innoviva, Inc. (NASDAQ:INVA – Free Report) by 2.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,066 shares of the biotechnology company’s stock after acquiring an additional 784 shares during […] - 2025-03-05 08:41:50

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc INVA holdings

Date	Number of INVA Shares Held	Base Market Value of INVA Shares	Local Market Value of INVA Shares	Change in INVA Shares Held	Change in INVA Base Value	Current Price per INVA Share Held	Previous Price per INVA Share Held
2025-09-26 (Friday)	6,394	USD 120,591	USD 120,591
2025-09-25 (Thursday)	6,394	USD 118,737	USD 118,737	0	USD -2,365	USD 18.5701	USD 18.9399
2025-09-24 (Wednesday)	6,394	USD 121,102	USD 121,102
2025-09-17 (Wednesday)	6,354	USD 123,141	USD 123,141	0	USD 255	USD 19.3801	USD 19.3399
2025-09-16 (Tuesday)	6,354	USD 122,886	USD 122,886
2025-09-12 (Friday)	6,314	USD 122,302	USD 122,302
2025-09-11 (Thursday)	6,314	USD 122,681	USD 122,681

Share Trades of INVA by Blackrock for IE00B3VWM098

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-08-21	SELL	-20			19.970*		18.89 Profit of 378 on sale
2025-07-31	BUY	60			18.170*		18.89
2025-06-30	SELL	-40			20.090*		18.83 Profit of 753 on sale
2025-06-25	SELL	-20			20.480*		18.80 Profit of 376 on sale
2025-06-20	SELL	-40			21.000*		18.76 Profit of 750 on sale
2025-05-23	BUY	20			18.970*		18.44
2025-05-19	SELL	-20			18.630*		18.43 Profit of 369 on sale
2025-05-15	SELL	-60			18.330*		18.43 Profit of 1,106 on sale
2025-05-12	SELL	-20			18.610*		18.43 Profit of 369 on sale
2025-05-09	SELL	-20			18.560*		18.43 Profit of 369 on sale
2025-04-30	SELL	-20			18.690*		18.41 Profit of 368 on sale
2025-04-24	SELL	-40			18.380*		18.42 Profit of 737 on sale
2025-04-17	SELL	-20			18.270*		18.42 Profit of 368 on sale
2025-04-15	SELL	-60			18.110*		18.43 Profit of 1,106 on sale
2025-04-14	SELL	-60			17.980*		18.43 Profit of 1,106 on sale
2025-04-09	SELL	-80			17.320*		18.47 Profit of 1,478 on sale
2025-04-07	SELL	-140			17.510*		18.50 Profit of 2,589 on sale
2025-04-04	SELL	-200			17.720*		18.50 Profit of 3,701 on sale
2025-03-31	BUY	20			18.130*		18.52
2025-03-19	SELL	-40			17.290*		18.63 Profit of 745 on sale
2025-03-14	SELL	-120			17.390*		18.68 Profit of 2,242 on sale
2025-03-13	SELL	-40			17.390*		18.70 Profit of 748 on sale
2025-03-12	SELL	-680			17.410*		18.72 Profit of 12,728 on sale
2025-03-07	SELL	-40			17.640*		18.77 Profit of 751 on sale
2025-03-06	SELL	-60			17.590*		18.79 Profit of 1,127 on sale
2025-03-03	SELL	-20			17.790*		18.84 Profit of 377 on sale
2025-02-28	SELL	-120			17.920*		18.86 Profit of 2,263 on sale
2025-02-26	SELL	-20			17.900*		18.89 Profit of 378 on sale
2025-02-25	SELL	-60			18.030*		18.91 Profit of 1,134 on sale
2025-02-18	BUY	100			18.030*		19.00
2025-02-13	BUY	20			18.220*		19.06
2025-02-12	BUY	20			17.980*		19.08
2025-02-11	BUY	60			18.060*		19.10
2025-02-06	BUY	180			18.260*		19.15
2025-01-27	BUY	20			18.980*		19.26
2024-12-30	BUY	100			17.380*		19.42
2024-12-06	BUY	80			19.050*		19.45
2024-12-05	BUY	20			18.920*		19.47
2024-12-04	BUY	100			18.870*		19.49
2024-11-29	BUY	100			18.990*		19.54
2024-11-27	BUY	80			19.050*		19.59
2024-11-26	BUY	20			19.140*		19.61
2024-11-21	BUY	100			19.060*		19.68
2024-11-20	BUY	60			19.150*		19.71
2024-11-18	BUY	240			18.950*		19.80
2024-11-12	BUY	160			20.320*		19.76
2024-11-08	BUY	100			20.180*		19.73
2024-11-07	BUY	300			20.000*		19.71
2024-11-06	BUY	40			19.920*		19.70
2024-10-31	BUY	20			19.560*		19.84

Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of INVA

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer